Serum α-SMA is a potential noninvasive biomarker of liver fibrosis

References

• Addissouky TA, Wang Y, Megahed FA. 2021. Novel biomarkers assist in detection of liver fibrosis in HCV patients. Egypt Liver J. 11:86.
   Google Scholar
• Aleknavičiūtė-Valienė G, Banys V. 2022. Clinical importance of laboratory biomarkers in liver fibrosis. Biochem Med (Zagreb). 32(3):030501. doi: 10.11613/BM.2022.030501.
   PubMed Web of Science ®Google Scholar
• Barcena-Varela M, Clyn , Fernandez-Barrena MG. 2019. Epigenetic mechanisms in hepatic stellate cell activation during liver fibrosis and carcinogenesis. Int J Mol Sci. 20(10):2507. doi: 10.3390/ijms20102507.
   PubMed Web of Science ®Google Scholar
• Bellan M, Castello LM, Pirisi M. 2018. Candidate biomarkers of liver fibrosis: a concise, pathophysiology-oriented review. J Clin Transl Hepatol. 6(3):317–325. doi: 10.14218/JCTH.2018.00006.
   PubMed Web of Science ®Google Scholar
• Cadranel JF, Rufat P, Degos F. 2000. Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology. 32(3):477–481. doi: 10.1053/jhep.2000.16602.
   PubMed Web of Science ®Google Scholar
• Casas-Grajales S, Vázquez-Flores LF, Ramos-Tovar E, Hernández-Aquino E, Flores-Beltrán RE, Cerda-García Rojas C, Camacho J, Shibayama M, Tsutsumi V, Muriel P. 2017. Quercetin reverses experimental cirrhosis by immunomodulation of the proinflammatory and profibrotic processes. Fundam Clin Pharmacol. 31(6):610–624. doi: 10.1111/fcp.12315.
   PubMed Web of Science ®Google Scholar
• Chang Y, Kim JI, Lee B, Kim SG, Jung MJ, Kim YS, Jeong SW, Jang JY, Yoo JJ. 2020. Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years. Clin Mol Hepatol. 26(3):318–327. doi: 10.3350/cmh.2019.0019n.
   PubMed Web of Science ®Google Scholar
• Chen VL, Du X, Chen Y, Kuppa A, Handelman SK, Vohnoutka RB, Peyser PA, Palmer ND, Bielak LF, Halligan B, et al. 2021. Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology. Nat Commun. 12(1):816. doi: 10.1038/s41467-020-20870-1.
   PubMed Web of Science ®Google Scholar
• Chin JL, Pavlides M, Moolla A, Ryan JD. 2016. Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy? Front Pharmacol. 7:159. doi: 10.3389/fphar.2016.00159.
   PubMed Web of Science ®Google Scholar
• Coombs PR, Warsa M, Hailu T, Agedew E, Tsegaye B. 2022. Establishing an ultrasound screening protocol for chronic liver disease with a handheld device: a pilot project in Southern Ethiopia. Ultrasound Med Biol. 48(4):702–710. doi: 10.1016/j.ultrasmedbio.2021.12.013.
   PubMed Web of Science ®Google Scholar
• Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, et al. 2020. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 26(10):1636–1643. doi: 10.1038/s41591-020-1051-9.
   PubMed Web of Science ®Google Scholar
• Fujita T, Narumiya S. 2016. Roles of hepatic stellate cells in liver inflammation: a new perspective. Inflamm Regen. 36(1):1. doi: 10.1186/s41232-016-0005-6.
   PubMedGoogle Scholar
• Garbuzenko DV. 2022. Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis. World J Clin Cases. 10(12):3662–3676. doi: 10.12998/wjcc.v10.i12.3662.
   PubMed Web of Science ®Google Scholar
• Guo T, Lok KY, Yu C, Li Z. 2014. Lung fibrosis: drug screening and disease biomarker identification with a lung slice culture model and subtracted cDNA library. Altern Lab Anim. 42(4):235–243. doi: 10.1177/026119291404200405.
   PubMed Web of Science ®Google Scholar
• He XL, Hu YH, Chen JM, Zhang DQ, Yang HL, Zhang LZ, Mu YP, Zhang H, Chen GF, Liu W, et al. 2022. SNS-032 attenuates liver fibrosis by anti-active heptic stellate cells via inhibition of cyclin dependent kinase 9. Front Pharmacol. 13:1016552. doi: 10.3389/fphar.2022.1016552.
   PubMed Web of Science ®Google Scholar
• Holm Nielsen S, Willumsen N, Leeming DJ, Daniels SJ, Brix S, Karsdal MA, Genovese F, Nielsen MJ. 2019. Serological assessment of activated fibroblasts by alpha-smooth muscle actin (α-SMA): a noninvasive biomarker of activated fibroblasts in lung disorders. Transl Oncol. 12(2):368–374. doi: 10.1016/j.tranon.2018.11.004.
   PubMed Web of Science ®Google Scholar
• Kamm DR, McCommis KS. 2022. Hepatic stellate cells in physiology and pathology. J Physiol. 600(8):1825–1837. doi: 10.1113/JP281061.
   PubMed Web of Science ®Google Scholar
• Kaur N, Goyal G, Garg R, Tapasvi C, Chawla S, Kaur R. 2021. Potential role of noninvasive biomarker during liver fibrosis. World J Hepatol. 13(12):1919–1935. doi: 10.4254/wjh.v13.i12.1919.
   PubMed Web of Science ®Google Scholar
• Koelman L, Pivovarova-Ramich O, Pfeiffer AF, Grune T, Aleksandrova K. 2019. Cytokines for evaluation of chronic inflammatory status in aging research: reliability and phenotypic characterisation. Immun Ageing. 16:11. doi: 10.1186/s12979-019-0151-1.
   PubMed Web of Science ®Google Scholar
• Lemoinne S, Thabut D, Housset C, Moreau R, Valla D, Boulanger CM, Rautou PE. 2014. The emerging roles of microvesicles in liver diseases. Nat Rev Gastroenterol Hepatol. 11(6):350–361. doi: 10.1038/nrgastro.2014.7.
   PubMed Web of Science ®Google Scholar
• Lominadze Z, Kallwitz ER. 2018. Misconception: you can’t have liver disease with normal liver chemistries. Clin Liver Dis (Hoboken). 12(4):96–99. doi: 10.1002/cld.742.
   PubMedGoogle Scholar
• Muriel P, Fernández-Martínez E, Montes S. 2017. Complications of cirrhosis: introduction. In: Muriel P, editor. Liver pathophysiology: therapies and antioxidants. Waltham (MA): Elsevier; p. 427–433.
   Google Scholar
• Muriel P. 2022. Monitoring of hepatic fibrosis. In: Muriel P, editor. Hepatic fibrosis: mechanisms and targets. San Diego (CA): Elsevier; p. 231–244.
   Google Scholar
• Nallagangula KS, Nagaraj SK, Venkataswamy L, Chandrappa M. 2018. Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression. Future Sci OA. 4(1):FSO250. doi: 10.4155/fsoa-2017-0083.
   PubMed Web of Science ®Google Scholar
• Önnerhag K, Hartman H, Nilsson PM, Lindgren S. 2019. Non-inasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). Scand J Gastroenterol. 54(3):328–334. doi: 10.1080/00365521.2019.1583366.
   PubMed Web of Science ®Google Scholar
• Paul J. 2020. Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. Egypt Liver J. 10(37):F1000.
   Google Scholar
• Qian T, Fujiwara N, Koneru B, Ono A, Kubota N, Jajoriya AK, Tung MG, Crouchet, E, Song W, Marquez CA, Panda G. 2022. Molecular signature predictive of long-term liver fibrosis progression to inform antifibrotic drug development. Gastroenterol. 162(4):1210–1225. doi: 10.1053/j.gastro.2021.12.250.
   PubMed Web of Science ®Google Scholar
• Ramos-Tovar E, Flores-Beltrán RE, Galindo-Gómez S, Camacho J, Tsutsumi V, Muriel P. 2019. An aqueous extract of Stevia rebaudiana variety Morita II prevents liver damage in a rat model of cirrhosis that mimics the human disease. Ann Hepatol. 18(3):472–479. doi: 10.1016/j.aohep.2018.10.002.
   PubMed Web of Science ®Google Scholar
• Ramos-Tovar E, Muriel P. 2022. Understanding the cellular and molecular mechanisms of hepatic fibrosis is essential for basic and clinical researchers. Ann Hepatol. 27(4):100732. doi: 10.1016/j.aohep.2022.100732.
   PubMed Web of Science ®Google Scholar
• Rosique-Oramas D, Martinez-Castillo Guzman C, Pérez-Hernández J, Cordova-Gallar J, Very-Pineda L, Higuera-De La Tijera F, Santana-Vargas D, Montalvo-Jave E, Sanchez-Avila F. 2019. Noninvasive biomarkers for the diagnosis of liver fibrosis and cirrhosis. In: Tsoulfas G, editor. Liver cirrhosis- debates and current challenges. London: IntechOpen; p. 84351.
   Google Scholar
• Shrivastava S, Mukherjee A, Ray RB. 2013. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol. 5(9):479–486. doi: 10.4254/wjh.v5.i9.479.
   PubMedGoogle Scholar
• Sumida Y, Nakajima A, Itoh Y. 2014. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 20(2):475–485. doi: 10.3748/wjg.v20.i2.475.
   PubMed Web of Science ®Google Scholar
• Tang A, Cloutier G, Szeverenyi NM, Sirlin CB. 2015. Ultrasound elastography and MR elastography for assessing liver fibrosis: part 1, principles and techniques. AJR Am J Roentgenol. 205(1):22–32. doi: 10.2214/AJR.15.14552.
   PubMed Web of Science ®Google Scholar
• Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, Yao Y, Ye T. 2021. Liver fibrosis: therapeutic targets and advances in drug therapy. Front Cell Dev Biol. 9:730176. doi: 10.3389/fcell.2021.730176.
   PubMed Web of Science ®Google Scholar
• Willumsen N, Bager CL, Leeming DJ, Smith V, Christiansen C, Karsdal MA, Dornan D, Bay-Jensen AC. 2014. Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer. Cancer Med. 3(5):1136–1145. doi: 10.1002/cam4.303.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhang Y, Sun B. 2022. The molecular mechanisms of liver fibrosis and its potential therapy in application. Int J Mol Sci. 23(20):12572. doi: 10.3390/ijms232012572.
   PubMed Web of Science ®Google Scholar
• Zhang L, Han C, Sun C, Meng H, Ye F, Na S, Chen F, Zhang D, Jin X. 2013. Serum levels of alpha-smooth muscle actin and c-Met as biomarkers of the degree of severity of Henoch-Schonlein purpura nephritis. Transl Res. 161(1):26–36. doi: 10.1016/j.trsl.2012.09.001.
   PubMed Web of Science ®Google Scholar